Become a Member

Topic Archives: Eli Lilly (LLY)

  • What’s Lashmet’s “Hunger Switch” Stock?

    Stansberry Venture Value pick hints lead to an obesity drug company whose "only competition is itself"

    10 Comments Read More
  • Friday File: NVIDIA by the Fingernails, Gold (and other shiny things), Energy Storage and more…

    What do Polish groceries, Ferraris, Giant Batteries, Mine Disasters and John Maynard Keynes have in common? Well, not much, but they're all in this week's Friday File... along with a trade or two.

    12 Comments Read More
  • Hernias, COVID, Obesity Drugs and Medicare Negotiation

    November 2023 Updates from Doc Gumshoe

    24 Comments Read More
  • Answers: Lashmet’s “Venture #87” — Teased as having the “potential for 400% Gains” starting October 31 as it “changes millions of lives”

    What's the latest urgent pick promotion from Stansberry Venture Technology?

    17 Comments Read More
  • Cancer 2023 – Second Installment

    In this follow-up to the previous Doc Gumshoe missive about cancer, entitled “Cancer 2023 – What’s Happening in the Combat Zone,” which posted on July 18, we’ll be discussing several general types of cancer – brain, lung, ovarian, breast, liver, and cancer caused by obesity. In each case, however, there are special conditions associated with […]

    6 Comments Read More
  • Cancer 2023: What’s Happening in the Combat Zone?

    Just over 50 years ago, President Richard M. Nixon signed into law the National Cancer Act of 1971, which established the National Cancer Institute. Cancer had become the second leading (after heart disease) cause of death in the US in 1970. The National Cancer Institute (NCI) from its establishment had broad powers, including the creation […]

    26 Comments Read More
  • Alzheimer’s Disease, RSV, Migraines and more…

    Doc Gumshoe's June 2023 Short Takes

    15 Comments Read More
  • Answers: “The Ultimate Weight Loss Drug” teased by Eifrig’s Prosperity Investor

    Finally, we take a short break from the A.I. mania to look at something else… this is the start of the pitch from Stansberry for Dr. David Eifrig’s Prosperity Investor(special deal is $2,500 for two years), with the ad introduced by Thomas Carroll, one of the analysts for that letter (John Engel is the other, […]

    31 Comments Read More
  • Weight and Waistline Worries

    Doc Gumshoe on BMI, Obesity and the latest wave of "weight loss" drugs

    22 Comments Read More
  • March 2023 Miscellany

    Doc Gumshoe finds the optimistic bits...

    14 Comments Read More
  • Osteoporosis Update (Part Two)

    Doc Gumshoe looks at diet, supplements and drugs

    13 Comments Read More
  • Odd & Ends – October 2022

    Doc Gumshoe on Alzheimer's, Lou Gehrig's Disease, drug pricing and more...

    21 Comments Read More
  • Stansberry Venture’s “Major Announcement” — What are the Three Companies facing a Wave of Money?

    New ads pitch a special report called "Three Ways to Make Triple-Digit Gains on Flash-Radioimmunotherapy," and we've got the Thinkolator results ... plus, a note about the also-teased "Incredible Weight-Loss Drug"

    22 Comments Read More
  • Following Up on Your Suggestions – September 2022

    Updates on Alzheimer's Disease, Anti-Inflammatories, Prostate Cancer, Vitamin D and more...

    20 Comments Read More
  • De-teasing the “Takeover Target for May” pitched by Dylan Jovine

    Will this latest tease benefit from the "Historic biotech merger wave?"

    15 Comments Read More
  • March 2022 Bulletins — Brief, but Relevant

    Doc Gumshoe looks at infections, weight-loss drugs, cataracts and dementia, Vitamin D supplements and more...

    23 Comments Read More
  • Eifrig’s “#1 Biotech Stock” and Four Teased Healthcare Plays

    What's being teased by Retirement Millionaire?

    40 Comments Read More
  • May Miscellany – Some Covid-19, Some Otherwise

    Doc Gumshoe looks at Herd Immunity, Vaccines and Treatments... plus some updates on Alzheimer's Disease, Dementia and more...

    33 Comments Read More
  • December 2020 COVID-19 Update: Focus On the Good (Or At Least Better) News

    Doc Gumshoe on progress in vaccines, treatments and immunity

    69 Comments Read More
  • Another Look at the Current Migraine Scene

    Thinking about COVID-19 almost gives me a migraine, or at least a heavy and achy sensation in my noggin – perhaps not an actual migraine, thankfully, but threatening and unpleasant all the same.   Happily, thinking about migraines will not give me COVID-19.   But migraines are by no means a topic of no consequence, […]

    13 Comments Read More
  • What’s that “First and Best Drugs” Alzheimer’s Stock for 300% gains?

    What's teased as the latest Alzheimer's Disease recommendation from Dave Lashmet for Stansberry's Investment Advisory?

    13 Comments Read More
  • Warm Bits for a Cold Month

    Doc Gumshoe on opioids, FDA approvals, and, yes the Wuhan Coronavirus

    26 Comments Read More
  • Alzheimer’s Disease: 2019 Refresher and Updates

    Doc Gumshoe's updated look at the "Grey Plague"

    56 Comments Read More
  • Combating Cancer: The Current Battle Plan

    Part Two of Doc Gumshoe's look at Cancer in 2019

    25 Comments Read More
  • Looking Backward – And a Peek in the Other Direction

    Doc Gumshoe looks at the state of cancer treatment... and some of the interesting drug approvals from 2018

    14 Comments Read More
  • Best Teaser Stocks of the Year

    We have a couple traditions here at Stock Gumshoe… we call out one of the worst teaser stock ideas around Thanksgiving and identify the “Turkey of the Year,” and then, as the year comes to a close and holiday merriment washes all around us, we call attention to the best teaser stocks of the year. […]

    9 Comments Read More
  • Migraine Update

    Hope for migraneurs? Doc Gumshoe takes another look

    11 Comments Read More
  • “Rising Healthcare Demand Enables 100+ Year Dividend-Paying Pharma Giant to Enter Best Dividend Stocks List”

    Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]

    8 Comments Read More
  • How Concerned Do We Need to Be About Drug Side Effects?

    Doc Gumshoe looks at the fine print

    16 Comments Read More
  • Two Flubs and a Big Question Mark

    Doc Gumshoe on "Female Viagra," CETP inhibitors and CRISPR

    22 Comments Read More
  • written by reader Alzheimer’s Wrap-Up

    Doc Gumshoe finishes his series on Alzheimer's Disease

    40 Comments Read More
  • Special Bulletin: The CoLucid IPO

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. You can see all of his articles archived here. Enjoy!] CoLucid Pharmaceuticals, which recently moved from Durham, NC, to Cambridge, MA, plans an initial public offering. Recent news suggests the […]

    Leave a comment Read More
  • The Long Case for Receptos

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]

    885 Comments Read More
  • written by reader Cancer Care: Where Are We and Where Are We Headed?

    [ed note: Michael Jorrin is a longtime medical writer (not a doctor) who covers health and medical topics and trends for our readers, generally without an investment thesis. His words are his own, enjoy!] In the Doc Gumshoe blog about cancer that appeared in June of 2013 (you can check it out here), I commented […]

    36 Comments Read More
  • The Finale is Grand: The Gain from Pain Mainly Explained

    DR. KSS ON THREE NEW COMPANIES FOR POTENTIAL PROFIT FROM PAIN

    856 Comments Read More
  • written by reader Payola from Portola?

    In his tearjerker “Sisters of Mercy,” Leonard Cohen sings, I’ve been where you’re hanging and think I can see how you’re pinned. Although I am less inclined to bash the FDA than many, it has recently let modern medical practice place many patients in an undesirable situation. What if there was a very powerful drug, […]

    932 Comments Read More
  • written by reader Biosimilars: What Are They, and Why On Earth Should We Care?

    Doc Gumshoe takes a look at "biologic generics"

    11 Comments Read More
  • written by reader Will This Unknown Boston Biotech Make Present Surgical Techniques Obsolete?

    Dr. KSS Looks at clotting for the Irregulars

    687 Comments Read More
  • Where is the Management of Type 2 Diabetes Heading?

    [ed note: Michael Jorrin, a medical writer who we have dubbed “Doc Gumshoe” (he’s not a doctor), shares his thoughts with us once or twice a month — what follows is his latest missive, the words and opinions below are his alone.] I didn’t plan it this way, but the timing of this Doc Gumshoe […]

    64 Comments Read More
  • written by reader Antibiotics Don’t Get No Respect, But You Can Still Profit From Them

    DR. KSS TAKES ON ANTIBIOTICS

    588 Comments Read More
  • Alzheimer’s Disease: Are There Any Glimmers of Light?

    [Ed. note: Michael Jorrin, who we like to call “Doc Gumshoe,” is not a doctor, he is a longtime medical writer who contributes pieces for us that we hope give a good background or perspective on medical issues (and marketing) for those of us who are as overwhelmed with “live to 150” promises as we […]

    39 Comments Read More
  • Can you really “Create Extra Paychecks Month After Month Thanks to the ‘MCR Plan?'” (Leeb)

    Figuring out the "Income Stacking" picks teased by Stephen Leeb's Complete Investor

    5 Comments Read More
  • Comments

  • Glad you were smarter than I was about LLY, never ended up buying it myself.I think Fluence is in decent shape, as...

  • I always get nervous when I find myself at odds with your wisdom. FLNC sits in an investment theme I feel strongly abo...

  • Almost certainly Eli Lilly's (LLY) Mounjaro (tirzepatide), Tilson has been talking up the weight loss drugs for a year o...

  • Yup moderrock, Viking looks very interesting. I've been following LLY and NVO for over a year and have done quite nice...

  • Looks like you had awfully good timing, with their Alzheimer's drug results helping spike the shares higher! Expensive ...

  • Haven't dug deep in either, my sense is that both LLY and NVO are expensive, but justifiably so, because of the massive ...

  • Travis: Thank you for the venture funding update and some background on Denali Therapeutics and their scientific resear...

  • I’m a “value investor”, retired, manage my own investment portfolio, and been a subscriber to Dr Eifrig ‘s new...

  • Promis Neurosciences (ARFXF) is tackling ALS, Alzheimer’s and Parkinson’s disease. I don’t know why these guys ar...

  • Latest News. Maybe, perhaps Lilly Strikes Collaboration With Swiss Biotech Basilea In Stomach Cancer StudyEli Lill...

  • That's what I'm seeing on the CDC site too - diabetes. And Eli Lilly bought a glucagon nasal spray from a small company ...

  • Eli Lilly finally published its disastrous EXPEDITION3 data, a costly lesson in rethinking Alzheimer’s https://twitt...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info